Skip to main content

LEQVIO is for LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1

.

2 INITIAL DOSES, THEN 2 DOSES A YEAR1

Dosing schedule is an initial dose, another at 3 months, and then once every 6 months

*After 2 initial doses and taken with statin therapy.1
Always check the expiration date on the prefilled syringe before administration.

  • No dose adjustments

  • No refrigeration1

  • Single-dose prefilled syringe1

  • Shelf life of 3 years2†

  • No required post-injection–related safety monitoring

Remember: Do not remove the needle cap until you are ready to inject.

For detailed instruction on administration, see Instructions for Use.

Dosing regimen may integrate seamlessly into a patient’s health care routine.

 

LEQVIO (inclisiran) injection

Remember: Do not remove the needle cap until you are ready to inject.

For detailed instruction on administration, see Instructions for Use.

Not actual size.
27 gauge, 1/2-inch needle.3

LEQVIO maintenance doses compared to Evolocumab maintenance doses

Alirocumab is dosed every 2 weeks (75 mg-150 mg), equating to 26 injections/year. The monthly dose of PCSK9 mAbs is administered by giving 2 or 3 injections consecutively, which equates to 24 to 36 injections/year.5
This is not a complete list of all the available treatments to patients with primary hyperlipidemia. The comparison pertains only to difference in dosing and administration and should not be considered a comparison of efficacy or safety. 

*After two initial doses and taken with statin therapy.1

Additional dosing information1

  • LEQVIO is administered into the abdomen, upper arm, or thigh

  • If a planned dose is missed by less than 3 months, administer LEQVIO and maintain dosing according to the patient's original schedule

  • If a planned dose is missed by more than 3 months, start a new dosing schedule—administer initially, again at 3 months, and then every 6 months

LEQVIO (inclisiran) injection can be administered in the abdomen, upper arm, or thigh

In-office administration1

  • In-office administration of LEQVIO adds minimal burden to your patients' existing medication and care regimen

  • Reduces LDL-C without adding an additional daily treatment

  • No specific label requirement for post-injection–related safety monitoring

  • Remember: Do not remove the needle cap until you are ready to inject

For detailed instruction on administration, see Instructions for Use.

THERE’S MORE TO KNOW ABOUT LEQVIO

Explore the LEQVIO mechanism of action

LDL-C, low-density lipoprotein cholesterol.

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Data on file. LEQVIO 3-Year Shelf Life. Novartis Pharmaceuticals Corp; 2022. 3. Data on file. LEQVIO Container Closure System. Novartis Pharmaceuticals Corp; 2022. 4. Repatha. Prescribing information. Amgen Inc. 5. Praluent. Prescribing information. Regeneron Pharmaceuticals Inc.